Funded by a nearly £1.2M (~$1.5M USD) award, this research will enable ongoing validation of AccelADx™, a breakthrough screening test for early detection of Alzheimer’s dementia. BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 11, 2024 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through […]

Cambridge, UK—10 July 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessments has been included in the Bio-Hermes 2 project for its voice and touch-screen cognitive assessments, funded by the UK’s innovation agency, Innovate UK.  The Bio-Hermes 2 trial, led by the Global Alzheimer’s Platform Foundation (GAP), aims to determine […]

10 July 2024 Innovate UK has awarded four UK companies a share of £4 million funding through Contracts for Innovation to support innovative research into dementia diagnosis. The funding will enable organisations to evaluate blood-based and digital biomarkers as part of the Bio-Hermes-002 study. This international study is led by the Global Alzheimer’s Platform Foundation® […]

Collaboration with Innovate UK Yields New Partners for Alzheimer’s Study Washington D.C., July 10, 2024- With groundbreaking creativity and breathtaking speed, this phase 3 competition, funded by Innovate UK, the UK’s innovation agency, is supporting organizations committed to improving dementia research using blood-based and digital biomarkers.   This competition received 14 proposals within one week, from […]

The Washington, D.C.-based Global Alzheimer’s Platform Foundation announced on July 8 that Snellville resident Tamiko MaGee-Rodgers has been named director of the foundation’s Recruitment and Strategic Initiatives. The nonprofit GAP was founded to speed the delivery of Alzheimer’s treatments with a commitment to promoting diversity in clinical research and lowering the cost and duration of […]

Washington D.C., July 8, 2024- Global Alzheimer’s Platform Foundation® (GAP) announced the appointment of Leigh Zisko, MPH as Chief Impact Officer and Tamiko MaGee-Rodgers, PhD, CCRP as the Director of Recruitment and Strategic Initiatives. In newly created global leadership roles, each will meaningfully contribute new perspectives and experience to GAP’s work in innovating clinical trial […]

Washington D.C., July 2, 2024- Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer applauds the U.S. Food and Drug Administration (FDA) for its decision granting full traditional approval of Eli Lilly and Company’s Kisunla™ (donanemab), a disease-modifying Alzheimer’s treatment for adults with early symptomatic Alzheimer’s disease (AD).  “Today, the FDA grants full approval for donanemab, […]

Washington D.C., July 1, 2024- The Food and Drug Administration (FDA) unveiled a draft guidance document, “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies,” which is open for public comment. This draft guidance points to improving participation from people who are traditionally underrepresented in clinical trials. John Dwyer, President […]

Resident contributor, Dr. Susan Steen breaks down three life changes to trackto prioritize your brain health as you and your loved ones age. As people age, it’s normal to experience occasional forgetfulness, however when does ‘some’ memory loss become a bigger concern? There are three aspects of your life that you can reflect on and […]

Global non-profit expands research network to the greater New Orleans areato improve access to research opportunities Washington D.C., June. 17, 2024- Global Alzheimer’s Platform Foundation® (GAP) is welcoming its first clinical research site from Louisiana into its network, Tandem Clinical Research of greater New Orleans. Tandem Clinical Research, a Prolerity Clinical Research Company site, advances […]

Washington D.C., June. 14, 2024- Global Alzheimer’s Platform Foundation® (GAP) proudly collaborated with The Global CEO Initiative on Alzheimer’s Disease (CEOi) to release the peer-reviewed publication of “Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease,” in Nature Reviews Neurology. Alzheimer’s blood tests have the […]

Washington D.C., June.10, 2024- Global Alzheimer’s Platform Foundation® (GAP) –applauds the U.S. Food and Drug Administration (FDA)’s acceptance of Eisai’s application for the subcutaneous maintenance dosing of Leqembi. With an action date set for January 25, 2025, this autoinjector will be used for weekly maintenance dosing and stands to reduce the burden on patients who are eligible to receive this disease-modifying therapy, as it can be used […]

Global Alzheimer’s Platform Foundation 2023 National Citizen Scientist Champion Award recipient Jeannie Weiss and Syrentis Clinical Research Vice President/Director of Clinical Operations Dr. Lorrie Bisesi join to discuss Alzheimer’s #octalkradio

Support from Scottish Parliament Underscores Its Significance Washington D.C., May 30, 2024-  The Global Alzheimer’s Platform Foundation® (GAP)  and the Scottish Funding Council’s Brain Health ARC have announced swift progress in the next steps of the Bio-Hermes Biomarker Data Challenge 2024, the research competition using the most comprehensive set of dementia biomarker data from ground-breaking […]

In the hands of the SFC-funded Brain Health ARC, the Bio-Hermes dataset offers the Scottish dementia research community a platform for new ideas, collaboration and early career development. Millie Mather explains more in our latest guest blog. During my working hours, I can be identified as the sole person in the room without a PhD in science or medicine. In fact, […]

Syrentis Clinical Research will hold a free memory screening event on Thursday, May 16, for people aged 50 and above to increase awareness for early detection of memory loss and Alzheimer’s disease. In California, it is estimated that more than 690,000 people are currently living with Alzheimer’s Disease, and experts predict that this number will […]

By:OCI Staff Syrentis Clinical Research will hold a free memory screening event on Thursday, May 16 for people aged 50 and above to increase awareness for early detection of memory loss and Alzheimer’s disease. In California, it is estimated that more than 690,000 people are currently living with Alzheimer’s Disease, and experts predict that this […]

By  Community News Releases, May 9, 2024 Visionary Investigators Network honored Joanne Bridges, the recipient of the 2023 National Citizen Scientist Collaborator Award® to recognize her extraordinary efforts as a study partner in an Alzheimer’s clinical trial at  Visionary Investigators Network. The Aventura mother and resident was selected as a National Honoree for the Global Alzheimer’s Platform Foundation® (GAP) Collaborator Award, from a […]

by Cathy Kelly, April 15, 2025 The agency’s projection that Medicare will spend $3.5bn on Leqembi in 2025 is nearly three times the level of sales that marketer Eisai is expecting for the drug in North and South America combined in its fiscal year 2026. The Centers for Medicare and Medicaid Services appear to be […]

trialsitenews Staff at TrialSite | Quality Journalism Apr. 12, 2024, 1:00 p.m. Expensive and not always covered by insurance, the standard most reliable method of diagnosing Alzheimer’s disease is via positron emission tomography or PET scan of the brain. Another more cumbersome, invasive and painful approach is the spinal tap. What if there was an […]

Costa Mesa resident Jeannie Weiss is driving Alzheimer’s research forward and is receiving a national award for her exemplary volunteerism to help advance science. The Global Alzheimer’s Platform Foundation (GAP) recognized Weiss for her exceptional role in Alzheimer’s research. Weiss received GAP’s 2023 National Citizen Scientist Champion Award, which is given to individuals who act […]

28th March 2024 Scotland has been selected to host a first-of-its-kind Alzheimer’s research competition, representing ‘significant recognition of the country’s wealth of world-leading expertise,’ says the Chief Scientist for Health Professor Anna Dominiczak welcomed the news that Scotland has already launched the Bio-Hermes Biomarker Data Challenge, granting access to what has been called “the most comprehensive […]

The Global Alzheimer’s Platform Foundation® (GAP) has announced that Scotland will host the Bio-Hermes Biomarker Data Challenge 2024, a groundbreaking research competition utilizing the most extensive collection of dementia biomarker data from innovative early blood testing studies for Alzheimer’s disease. Researchers at the Universities of Glasgow and St. Andrews, under the auspices of the Scottish […]

Washington D.C., Mar. 25, 2024- The Global Alzheimer’s Platform Foundation® (GAP) – which is focused on global game-changing dementia research – has chosen Scotland to host the Bio-Hermes Biomarker Data Challenge 2024, a research competition using the most comprehensive set of dementia biomarker data from ground-breaking early blood testing studies for Alzheimer’s disease. Researchers at […]